Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ <scp>PROTECT</scp> Main Study
This is a plain language summary describing results from the Alfa-PROTECT study on safety and efficacy of damoctocog alfa pegol in previously treated children aged between 7 and 12 years with severe haemophilia A. Trial Registration: The Alfa-PROTECT trial is registered at ClinicalTrials.gov: NCT05147662.
Authors
- Mauro Dávoli (ORCID: https://orcid.org/0000-0003-0584-1901)
- Gregory C. Makris (ORCID: https://orcid.org/0000-0003-3437-621X)
- Claudia Tueckmantel
- Kaan Kavaklı (ORCID: https://orcid.org/0000-0002-4910-2142)
- Shveta Gupta
- Anthony K. C. Chan
- Mario Guillermo Arbesú
- Matteo Luciani
- Luciana C. Oliveira
- Monika Maas Enriquez
- Maria Elisa Mancuso
- Nasrin Samji
- Margareth C. Ozelo
- Heidi Glosli
Institutions
- University of Mendoza (AR)
- Oslo University Hospital (NO)
- Universidade de Ribeirão Preto (BR)
- Humanitas University (IT)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Arnold Palmer Hospital for Children (US)
- McMaster Children's Hospital (CA)
- Ege University (TR)
- National Hospital (IN)
- Bambino Gesù Children's Hospital (IT)
- Fundação Hemopa (BR)
- Instituto Cardiovascular de Rosario (AR)
- IRCCS Humanitas Research Hospital (IT)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1111/ejh.70078
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00